{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:21:13Z","timestamp":1760145673479,"version":"build-2065373602"},"reference-count":17,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T00:00:00Z","timestamp":1723161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Children"],"abstract":"<jats:p>We report on a 4-year-old boy affected by Gaucher disease (GD) type 3, who presented with splenomegaly and a history of oculomotor apraxia. GD is a rare lysosomal storage disorder caused by glucocerebrosidase deficiency with multi-organ involvement. Besides common clinical features such as hepatosplenomegaly and skeletal involvement, less frequent neurological symptoms, such as oculomotor apraxia, are indicative of neuronopathic forms of the disease, namely GD type 3, to be confirmed both by enzyme activity and genetic testing. Overall, GD management requires a multidisciplinary approach involving metabolic pediatricians, neurologists, psychologists, and geneticists, and currently relies on early enzyme replacement therapy. Although enzyme replacement therapy has proved to be effective in improving systemic signs and symptoms, it is unable to alleviate neurological complications once these have occurred, as it does not pass across the blood\u2013brain barrier. Neurological improvements may occur through indirect mechanisms. Thus, our case report aims to highlight the importance of considering GD in the differential diagnosis of pediatric patients presenting with splenomegaly associated with neurological manifestations, as early intervention may significantly modify the disease progression and prevent further irreversible complications.<\/jats:p>","DOI":"10.3390\/children11080960","type":"journal-article","created":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T05:23:27Z","timestamp":1723613007000},"page":"960","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pediatric Gaucher Disease Type 3 Presenting with Oculomotor Apraxia: A Case Report"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8985-770X","authenticated-orcid":false,"given":"Margherita","family":"Di Costanzo","sequence":"first","affiliation":[{"name":"Pediatrics and Neonatology Unit, Guglielmo da Saliceto Hospital, 29121 Piacenza, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2187-6813","authenticated-orcid":false,"given":"Nicoletta","family":"de Paulis","sequence":"additional","affiliation":[{"name":"Pediatrics and Neonatology Unit, Guglielmo da Saliceto Hospital, 29121 Piacenza, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0308-2825","authenticated-orcid":false,"given":"Giuseppe","family":"Cannalire","sequence":"additional","affiliation":[{"name":"Pediatrics and Neonatology Unit, Guglielmo da Saliceto Hospital, 29121 Piacenza, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3787-2243","authenticated-orcid":false,"given":"Nicola","family":"Morelli","sequence":"additional","affiliation":[{"name":"Diagnostic Neuroradiology Unit, Department of Radiological Functions, Guglielmo da Saliceto Hospital, 29121 Piacenza, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7441-9248","authenticated-orcid":false,"given":"Giacomo","family":"Biasucci","sequence":"additional","affiliation":[{"name":"Pediatrics and Neonatology Unit, Guglielmo da Saliceto Hospital, 29121 Piacenza, Italy"},{"name":"Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,8,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ymgme.2022.03.001","article-title":"The diagnosis and management of Gaucher disease in pediatric patients: Where do we go from here?","volume":"136","author":"Weinreb","year":"2022","journal-title":"Mol. Genet. Metab."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1002\/pbc.25165","article-title":"Early diagnosis of Gaucher disease in pediatric patients: Proposal for a diagnostic algorithm","volume":"61","author":"Andria","year":"2014","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Stirnemann, J., Belmatoug, N., Camou, F., Serratrice, C., Froissart, R., Caillaud, C., Levade, T., Astudillo, L., Serratrice, J., and Brassier, A. (2017). A review of Gaucher disease pathophysiology, clinical presentation and treatments. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18020441"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ymgme.2019.05.011","article-title":"Gaucher disease type 3c: New patients with unique presentations and review of the literature","volume":"127","author":"Kurolap","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1212\/WNL.54.1.261","article-title":"Gaucher disease with oculomotor apraxia and cardiovascular calcification (Gaucher type IIIC)","volume":"54","author":"Bohlega","year":"2000","journal-title":"Neurology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1089\/cap.2014.0084","article-title":"Clinical Evaluation of Youth with PediatricAcute-Onset Neuropsychiatric Syndrome (PANS): Recommendations from the 2013 PANS Consensus Conference","volume":"25","author":"Chang","year":"2015","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.pediatrneurol.2014.10.016","article-title":"Oculomotor apraxia in Gaucher disease","volume":"52","author":"Nagappa","year":"2015","journal-title":"Pediatr. Neurol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/jbmr.3734","article-title":"Gaucher Disease in Bone: From Pathophysiology to Practice","volume":"34","author":"Hughes","year":"2019","journal-title":"J. Bone Miner. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/17446651.2018.1445524","article-title":"Recent advances in the diagnosis and management of Gaucher disease","volume":"13","author":"Gary","year":"2018","journal-title":"Expert Rev. Endocrinol. Metab."},{"key":"ref_10","first-page":"CD010324","article-title":"Enzyme replacement and substrate reduction therapy for Gaucher disease","volume":"2015","author":"Shemesh","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Kulkarni, A., Chen, T., Sidransky, E., and Han, T.U. (2024). Advancements in Viral Gene Therapy for Gaucher Disease. Genes, 15.","DOI":"10.3390\/genes15030364"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Pavan, E., Ormazabal, M., Peruzzo, P., Vaena, E., Rozenfeld, P., and Dardis, A. (2020). CRISPR\/Cas9 Editing for Gaucher Disease Modelling. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21093268"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Mohamed, F.E., and Al-Jasmi, F. (2024). Exploring the efficacy and safety of Ambroxol in Gaucher disease: An overview of clinical studies. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1335058"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1016\/j.ymgme.2016.11.175","article-title":"Role of oxidative stress and inflammation in type 1 Gaucher disease (GD1): Potential use of antioxidant\/anti-inflammatory medications","volume":"120","author":"Kartha","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/s13023-022-02378-7","article-title":"Thirty-year clinical outcomes after haematopoietic stem cell transplantation in neuronopathic Gaucher disease","volume":"17","author":"Donald","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"108515","DOI":"10.1016\/j.ymgme.2024.108515","article-title":"Hematopoietic stem cell transplantation or enzyme replacement therapy in Gaucher disease type 3","volume":"142","author":"Naume","year":"2024","journal-title":"Mol. Genet. Metab."},{"key":"ref_17","first-page":"82","article-title":"Management of Gaucher disease: Enzyme replacement therapy","volume":"12","author":"Elstein","year":"2014","journal-title":"Pediatr. Endocrinol. Rev."}],"container-title":["Children"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9067\/11\/8\/960\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:34:13Z","timestamp":1760110453000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9067\/11\/8\/960"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,9]]},"references-count":17,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["children11080960"],"URL":"https:\/\/doi.org\/10.3390\/children11080960","relation":{},"ISSN":["2227-9067"],"issn-type":[{"type":"electronic","value":"2227-9067"}],"subject":[],"published":{"date-parts":[[2024,8,9]]}}}